The sale of Chemours' glycolic acid business to PureTech Scientific for $137 million could have a positive impact on the company's stock price. The deal may be seen as a strategic move to focus on core businesses and generate cash from non-core assets. This could lead to a positive market reaction and an increase in the stock price in the short term.